<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (date of earliest event reported):
May 21, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Asterias Biotherapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: white">
    <TD STYLE="width: 33%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Delaware</b></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="width: 33%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>001-36646</b></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="width: 33%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>46-1047971</b></font></td></tr>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<tr style="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of <BR>
incorporation)</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</font></td></tr>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>230 Constitution Drive&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Menlo Park, California 94025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(650) 433-2900</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#146;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: top">
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: top">
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: top">
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: top">
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</table>
<P STYLE="font: 10pt inherit,serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt inherit,serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt inherit,serif; margin: 0pt 0"><B>Item 3.02 Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt inherit,serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As announced in a press release, dated May 26, 2015, on
May 21, 2015, Asterias Biotherapeutics, Inc. (the &#147;Company&#148;) issued an aggregate of 5,000,000 shares of Series A Common
Stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of the Company, pursuant to the exercise of all outstanding
warrants to purchase Common Stock that were originally issued by it in June 2014 (the &#147;Warrants&#148;). The Warrants were
exercised in full prior to their expiry on June 15, 2015. Each Warrant was exercisable for cash at $2.34 per share of Common Stock,
resulting in gross proceeds to the Company of $11.7 million.</P>

<P STYLE="font: 10pt inherit,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The shares of Common Stock issued upon exercise of the
Warrants were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;) under Regulation D and Section 4(a)(2) of the Securities Act and have not been registered under the Securities Act,
and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. The Company
has filed a resale registration statement on Form S-3 with the Securities and Exchange Commission for purposes of registering the
resale of the shares of Common Stock issued upon exercise of the Warrants.</P>

<P STYLE="font: 10pt inherit,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01. Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td nowrap style="width: 15%; border-bottom: black 1pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Exhibit Number</b></font></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 84%; border-bottom: black 1pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Description</b></font></td></tr>
<tr>
    <td nowrap style="vertical-align: top; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif">&nbsp;</td></tr>
<tr>
    <td nowrap style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">99.1</font></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Press release, dated May 26, 2015, issued by Asterias Biotherapeutics, Inc.</font></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
<tr>
    <td style="width: 100%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>ASTERIAS BIOTHERAPEUTICS, INC.</b></font></td>
    <td style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="font-family: Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif">Date: May 26, 2015</font></td>
    <td style="width: 3%; font-family: Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif">By:</font></td>
    <td style="width: 52%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>/s/ Robert W. Peabody</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></td>
    <td style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</td>
    <td style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;</td></tr>
</table>


<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "s000927x1_8k.htm", "description": "8-K", "secsgml_size_bytes": 15639}]
{"company-data": {"conformed-name": "Asterias Biotherapeutics, Inc.", "cik": "0001572552", "assigned-sic": "2836", "irs-number": "461047971", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36646", "film-number": "15889737"}, "business-address": {"street1": "230 CONSTITUTION DRIVE", "city": "MENLO PARK", "state": "CA", "zip": "94025", "phone": "510-521-3390"}, "mail-address": {"street1": "230 CONSTITUTION DRIVE", "city": "MENLO PARK", "state": "CA", "zip": "94025"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
May 21, 2015
Asterias Biotherapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
001-36646
46-1047971
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer Identification No.)
230 Constitution Drive
Menlo Park, California 94025
(Address of principal executive offices)
(650) 433-2900
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.02 Unregistered Sales of Equity Securities.
As announced in a press release, dated May 26, 2015, on
May 21, 2015, Asterias Biotherapeutics, Inc. (the "Company") issued an aggregate of 5,000,000 shares of Series A Common
Stock, par value $0.0001 per share (the "Common Stock"), of the Company, pursuant to the exercise of all outstanding
warrants to purchase Common Stock that were originally issued by it in June 2014 (the "Warrants"). The Warrants were
exercised in full prior to their expiry on June 15, 2015. Each Warrant was exercisable for cash at $2.34 per share of Common Stock,
resulting in gross proceeds to the Company of $11.7 million.
The shares of Common Stock issued upon exercise of the
Warrants were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended (the "Securities
Act") under Regulation D and Section 4(a)(2) of the Securities Act and have not been registered under the Securities Act,
and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. The Company
has filed a resale registration statement on Form S-3 with the Securities and Exchange Commission for purposes of registering the
resale of the shares of Common Stock issued upon exercise of the Warrants.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
Exhibit Number
Description
99.1
Press release, dated May 26, 2015, issued by Asterias Biotherapeutics, Inc.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ASTERIAS BIOTHERAPEUTICS, INC.
Date: May 26, 2015
By:
/s/ Robert W. Peabody
Chief Financial Officer